The ISN's Sister Renal Center program

Rashad Barsoum

doi:10.1038/ncpneph0380 | Full Text | PDF (52K)

A new look at an old problem: therapy of chronic hyponatremia

Mitchell L Halperin and Kamel S Kamel

Taking into account the danger of provoking osmotic demyelination by causing an overly rapid rise in the plasma sodium level, these authors from the University of Toronto offer their recommendations for correcting chronic hyponatremia. They highlight the importance of avoiding a substantial water diuresis, and discuss three key clinical settings where such a diuresis can occur.

doi:10.1038/ncpneph0375 | Full Text | PDF (84K)

Ciclosporin A for the treatment of refractory proteinuria in pediatric lupus nephritis

doi:10.1038/ncpneph0340 | Full Text | PDF (59K)

Outpatient alcohol cyst sclerotherapy relieves flank pain associated with ADPKD

doi:10.1038/ncpneph0350 | Full Text | PDF (74K)

Brachio–brachial fistula proposed as an alternative to prosthetic grafts

doi:10.1038/ncpneph0354 | Full Text | PDF (58K)

COX2 inhibitors: effect on arrhythmia and renal adverse events

doi:10.1038/ncpneph0337 | Full Text | PDF (58K)

European Best Practice Guidelines for Peritoneal Dialysis acknowledged by ISN

Omar Abboud, Rashad Barsoum, Francois Berthoux, Michael Field, Richard Johnson, Shanyan Lin and Pablo Massari

doi:10.1038/ncpneph0381 | Full Text | PDF (84K)

Superimposing candesartan onto ACE inhibition slows renal function decline in nondiabetic chronic kidney disease

Niels H Andersen

doi:10.1038/ncpneph0348 | Full Text | PDF (87K)

Benefit of acetylcysteine for prevention of contrast-induced nephropathy after primary angioplasty

Bernhard K Krämer and Ute Hoffmann

doi:10.1038/ncpneph0346 | Full Text | PDF (88K)

Optimal paricalcitol starting dose for parathyroid hormone suppression in secondary hyperparathyroidism

David A Bushinsky

doi:10.1038/ncpneph0363 | Full Text | PDF (90K)

Predicting outcomes of peritoneal-dialysis-associated peritonitis based on dialysate white blood cell count

Mark D Faber

doi:10.1038/ncpneph0360 | Full Text | PDF (87K)

Is it premature to use calcineurin-inhibitor-free immunosuppression in pediatric renal transplantation?

Guido Filler

doi:10.1038/ncpneph0361 | Full Text | PDF (85K)

When should post-transplantation proteinuria be attributed to the renal allograft rather than to the native kidney?

Christian Morath and Martin Zeier

doi:10.1038/ncpneph0376 | Full Text | PDF (87K)

Anemia in diabetes: marker or mediator of microvascular disease?

Merlin C Thomas

One in five patients with diabetic kidney dysfunction is anemic. Low hemoglobin levels in this population are associated with an increased risk of progression to end-stage renal disease, increased cardiovascular morbidity and mortality, hypertension, retinopathy, neuropathy and foot ulcers. Here, Merlin Thomas from the Baker Medical Research Institute in Melbourne explores the pathophysiology of anemia in diabetic kidney disease, and the clinical utility of its correction.

doi:10.1038/ncpneph0378 | Full Text | PDF (704K)

Living donor renal transplantation: recent developments and perspectives

Seema Baid-Agrawal and Ulrich A Frei

A new source of organs became available following the first successful transplantation of a kidney from a living donor half a century ago. Since then, expanding the living donor pool has been a priority. This appraisal of strategies used to increase the number of living kidney donors focuses on transplantation across ABO and HLA barriers, and extending selection criteria to include elderly and obese donors, and those with hypertension.

doi:10.1038/ncpneph0383 | Full Text | PDF (289K)

Mechanisms of Disease: the role of aldosterone in kidney damage and clinical benefits of its blockade

Lucia Del Vecchio, Mirella Procaccio, Sara Viganò and Daniele Cusi

Experimental data support a role for aldosterone in renal injury that is independent of renin and angiotensin II, and indicate that blocking the activity of this mineralocorticoid might ameliorate progression of chronic kidney disease. Lucia Del Vecchio and colleagues discuss these findings. The authors also review preliminary clinical trial data, which are consistent with a significant antiproteinuric effect of aldosterone antagonists such as spironolactone.

doi:10.1038/ncpneph0362 | Full Text | PDF (214K)